Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811874 | 1.00 | PDGFRB (0.54) | PDGFRBPDGFRAAXLFGFR2EGFR | |
| SCHEMBL4462225 | 0.86 | PDGFRA (0.56) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL22265563 | 0.85 | AXL (0.54) | PDGFRAAXLFGFR2KDRKIT | |
| SCHEMBL14967538 | 0.84 | PDGFRB (0.57) | PDGFRBPDGFRAAXLFGFR2EGFR | |
| SCHEMBL166914 | 0.83 | AXL (0.67) | PDGFRBPDGFRAAXLFGFR2KDR | |
| SCHEMBL17035605 | 0.82 | AXL (0.66) | PDGFRBPDGFRAAXLFGFR2KDR | |
| Hydrochloric Acid SCHEMBL30388215 | 0.82 | AXL (0.66) | PDGFRBPDGFRAAXLFGFR2KDR | |
| Hydrochloric Acid SCHEMBL21776567 | 0.82 | AXL (0.66) | PDGFRBPDGFRAAXLFGFR2KDR | |
| SCHEMBL31554494 | 0.82 | KIT (0.45) | PDGFRBPDGFRAEGFRKDRKIT | |
| SCHEMBL21753513 | 0.81 | PDGFRB (0.59) | PDGFRBPDGFRAFGFR2EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4034532-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | Exelixis, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021062245-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | EXELIXIS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | PDGFRB 1297/4885PDGFRA 1935/4885AXL 1100/4885 |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | PDGFRB 1297/4885PDGFRA 1935/4885AXL 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.